Business Context and Reporting Period
Company: Aclaris Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 8, 2017
Reporting Period: Second quarter and six months ended June 30, 2017
Context: The registrant filed this report to announce financial results for the specified period and to provide details regarding a conference call to discuss these results and business updates. The company is designated as an emerging growth company.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) for detailed data. Consequently, the filing text itself does not provide specific values for the following metrics:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt
- Liquidity
Note: Specific financial figures are contained in the referenced press release and are not present in the text of this 8-K form.
Material Changes
The filing text does not contain specific data regarding material changes versus the prior comparable period. It only indicates that such results were announced in the accompanying press release.
Guidance, Outlook, and Risks
Management Commentary: The company announced a conference call to discuss financial results and business updates.
Legal Disclaimer: In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 and the attached press release is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and is not subject to the liability of that section. It shall not be deemed incorporated by reference in any other filings unless expressly set forth by specific reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 8, 2017) for actual revenue, net loss, and cash position figures.
- Verify the specific details of the "business updates" mentioned in the conference call announcement.
- Confirm the company's status as an emerging growth company and its election regarding the extended transition period for accounting standards.
- Note that the financial data in the press release is not legally "filed" under Section 18 of the Exchange Act per the disclaimer in this 8-K.